CytoSorbents Stock Price

0.03 (0.37%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CytoSorbents Corporation CTSO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 0.37% 8.06 18:00:00
Open Price Low Price High Price Close Price Prev Close
8.11 7.91 8.11 8.06 8.03
Bid Price Ask Price Spread News
8.00 9.00 1.00 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,701 176,900 $ 8.00 $ 1,415,332 - 6.99 - 11.684
Last Trade Time Type Quantity Stock Price Currency
17:37:19 91 $ 8.06 USD


Draw Mode:

CytoSorbents Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 347.85M 43.16M 31.77M $ 41.00M $ -9.46M -0.59 -36.79
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 3.00 65.20%

more financials information »

CytoSorbents News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTSO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.538.627.918.23138,056-0.47-5.51%
1 Month9.599.807.918.89240,310-1.53-15.95%
3 Months7.79789.806.998.29289,9730.26223.36%
6 Months8.489.806.998.34250,452-0.42-4.95%
1 Year7.9211.6846.998.76278,6050.141.77%
3 Years12.8013.893.497.89328,619-4.74-37.03%
5 Years6.2114.953.307.93263,9761.8529.79%

CytoSorbents Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.